Why Is BIOCRYST PHARMACEUTI (BCRX) Stock Down Today?

BCRX stock closed down 7.98% at $9.16 on September 8, marking a significant decline driven by intraday volatility and broader market sentiment. The stock opened with a 1.0% gap up at $10.06 but quickly reversed course, hitting a session low of $8.96 before settling near the bottom of its intraday range. The move occurred despite recent analyst upgrades and regulatory progress for the company’s key drug, ORLADEYO.

What Happened

BioCryst Pharmaceuticals shares opened at $10.06, but momentum failed to hold as the stock drifted lower throughout the session. By the close, it had fallen to $9.16, a decline of 7.98%. The stock traded at its lowest level since July and near the lower end of its 52-week range. While the company recently received regulatory approval for ORLADEYO in Japan for pediatric HAE patients, the stock failed to sustain positive momentum. Analysts at TD Cowen initiated coverage with a Buy rating, and RBC Capital and Wedbush both maintained Outperform ratings, though with lowered price targets. Despite these developments, the stock’s performance suggests investor skepticism or profit-taking following recent gains.

What The Data Shows

The stock traded 6.6 million shares, 1.5 times its 3-month average, indicating heightened interest. The intraday session showed a sharp reversal from its opening high to its closing low. BioCryst remains unprofitable, with a TTM net margin of -40.9% and a TTM revenue increase of 68.7%. The 52-week tape recorded six fresh 52-week lows on the same day, underscoring the stock’s recent weakness. Sentiment has also deteriorated, with a 7-day average of 59 out of 100, down from a 30-day average of 64.

What To Watch

BioCryst has no scheduled earnings report in the immediate outlook. Investors should monitor coverage breadth and analyst price target adjustments for potential catalysts.